Author

Marie Reeberg Sass

Observed name: Marie R. Sass

Institution: Novo Nordisk (Denmark)

Observed institutions: University of Copenhagen, Novo Nordisk (Denmark), Mental Health Services, Copenhagen University Hospital, Rigshospitalet, Capital Region of Denmark, Novo Nordisk Foundation Center for Basic Metabolic Research

ORCID: 0000-0002-0934-8463

Observed ORCID: 0000-0002-0934-8463

OpenAlex ID: A5015849186

Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)

2023 · Marie Reeberg Sass, Andreas Aalkjær Danielsen, et al. · BMJ Open · 38

Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders

2025 · Marie R. Sass, Mette Kruse Klausen, et al. · JAMA Psychiatry · 23

Secretion of parathyroid hormone may be coupled to insulin secretion in humans

2020 · Marie Reeberg Sass, Nicolai Jacob Wewer Albrechtsen, et al. · Endocrine Connections · 12

Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26‐week open‐label feasibility study

2024 · Marie Reeberg Sass, Anne Mette Brandt Christensen, et al. · Acta Psychiatrica Scandinavica · 4

SARS-CoV-2 seroprevalence among patients with severe mental illness: A cross-sectional study

2022 · Marie Reeberg Sass, Tobias Søgaard Juul, et al. · PLoS ONE · 4

Alzheimer's disease Stage 1 and 2: Biology, diagnostics, and treatment

2026 · Suzanne E. Schindler, Oskar Hansson, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 3

Author response for "Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26‐week open‐label feasibility study"

2024 · Marie Reeberg Sass, Anne Mette Brandt Christensen, et al.

Author response for "Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26‐week open‐label feasibility study"

2024 · Marie Reeberg Sass, Anne Mette Brandt Christensen, et al.

Works count: 8

Citation count: 84

H-index: 4

I10-index: 3